PRF Technologies (PRFX) Total Non-Current Liabilities (2019 - 2025)
PRF Technologies (PRFX) posted quarterly Total Non-Current Liabilities of $267000.0 for Q4 2025, up 3.09% year-on-year from $259000.0 in Q4 2024, and up 1.52% on a QoQ basis from $263000.0 in Q2 2025.
PRF Technologies (PRFX) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Total Non-Current Liabilities for 7 consecutive years, with $267000.0 the latest figure, recorded in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 3.09% year-over-year to $267000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $267000.0 (up 3.09% YoY) and the FY2025 annual result came in at $267000.0, up 3.09% from the prior year.
- Total Non-Current Liabilities climbed to $267000.0 in Q4 2025 per PRFX's latest filing, from $263000.0 in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for PRFX reached as high as $1.2 million in Q3 2023 and fell as low as $213000.0 in Q1 2021.
- A 5-year average of $412000.0 and a median of $259000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 367.08% — and 2024, when it slumped 77.18%.
- Year by year, Total Non-Current Liabilities stood at $234000.0 in 2021, then increased by 3.85% to $243000.0 in 2022, then surged by 367.08% to $1.1 million in 2023, then sank by 77.18% to $259000.0 in 2024, then grew by 3.09% to $267000.0 in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $267000.0, $263000.0, and $259000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | 267,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 267,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Dec 31, 2024 | 259,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.15 Mn |
| Jun 30, 2023 | 247,000.00 |
| Mar 31, 2023 | 245,000.00 |
| Dec 31, 2022 | 243,000.00 |
| Jun 30, 2022 | 549,000.00 |
| Mar 31, 2022 | 236,000.00 |
| Dec 31, 2021 | 234,000.00 |
| Jun 30, 2021 | 613,000.00 |
| Mar 31, 2021 | 213,000.00 |
| Dec 31, 2020 | 220,000.00 |
| Sep 30, 2020 | -1.07 Mn |
| Jun 30, 2020 | 1.51 Mn |
| Mar 31, 2020 | -802,000.00 |
| Dec 31, 2019 | 447,000.00 |